We will start our first talc trial in St. Louis this month. The trial involving Johnson & Johnson and Luzenac America was scheduled to commence on Feb. 1 and at press time it was still on. This case involves J&J’s talcum powder products, the companies knowledge of the risk of ovarian cancer and the failure by J&J to warn users of the risk.
To this day, both J&J and Luzenac America has never warned women who use the products about the cancer risk. Luzenac did issue a warning, however, it went to J&J. The trial is expected to last for about three weeks. We currently represent 6,200 individuals in this litigation, and this trial is important – not just to all clients – but also to thousands of victims and their families.